Want to join the conversation?
$ANGO saw growth in the Peripheral Vascular franchise in 1Q17 due to the opportunities created by its competitor's (Cook Medical) recall of its angiographic products. Across the business, $ANGO also delivered good performance in BioFlo Midline and Dialysis in the Vascular Access franchise and growth for NanoKnife and Microwave in Oncology/Surgery.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.